Tesetaxel
- Generic Name
- Tesetaxel
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C46H60FN3O13
- CAS Number
- 333754-36-2
- Unique Ingredient Identifier
- UG97LO5M8Y
- Background
Tesetaxel has been used in trials studying the treatment of Cancer, Melanoma, Prostate Cancer, Gastric Carcinoma, and Advanced Melanoma, among others.
- Associated Conditions
- -
- Associated Therapies
- -
The Effect of Tesetaxel on the QTc Interval and the Effect of Food, Itraconazole, and Rifampin on Tesetaxel Pharmacokinetics in Patients With Advanced Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2020-03-18
- Last Posted Date
- 2021-07-28
- Lead Sponsor
- Odonate Therapeutics, Inc.
- Target Recruit Count
- 93
- Registration Number
- NCT04312282
- Locations
- 🇺🇸
NEXT Oncology, San Antonio, Texas, United States
🇺🇸Mary Crowley Cancer Research, Dallas, Texas, United States
🇺🇸START Midwest, Grand Rapids, Michigan, United States
Tesetaxel Plus 3 Different PD-(L)1 Inhibitors in Patients With Triple-Negative MBC and Tesetaxel Monotherapy in Patients With HER2-Negative MBC
- Conditions
- Interventions
- First Posted Date
- 2019-05-16
- Last Posted Date
- 2021-07-30
- Lead Sponsor
- Odonate Therapeutics, Inc.
- Target Recruit Count
- 294
- Registration Number
- NCT03952325
- Locations
- 🇺🇸
West Cancer Center, Germantown, Tennessee, United States
🇸🇬National Cancer Centre Singapore, Singapore, Singapore
🇺🇸Sarah Cannon Research Institute - Florida Cancer Specialists, Fort Myers, Florida, United States
Tesetaxel Plus Reduced Dose of Capecitabine in Patients With HER2 Negative, HR Positive, LA/MBC
- First Posted Date
- 2019-03-01
- Last Posted Date
- 2021-07-30
- Lead Sponsor
- Odonate Therapeutics, Inc.
- Target Recruit Count
- 152
- Registration Number
- NCT03858972
- Locations
- 🇺🇸
Texas Oncology - Baylor Charles A. Sammons Cancer Center, Dallas, Texas, United States
🇰🇷Asan Medical Center, Seoul, Korea, Republic of
🇨🇦Hopital Maisonneuve-Rosemont, Montréal, Canada
Tesetaxel Every 3 Weeks vs Weekly vs Capecitabine as 1st-line Therapy for Locally Advanced or Metastatic Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2012-05-31
- Last Posted Date
- 2012-06-01
- Lead Sponsor
- Genta Incorporated
- Target Recruit Count
- 213
- Registration Number
- NCT01609127
- Locations
- 🇺🇸
The West Clinic, Memphis, Tennessee, United States
Capecitabine/Tesetaxel Versus Capecitabine/Placebo as Second-line Therapy for Gastric Cancer
- First Posted Date
- 2012-04-09
- Last Posted Date
- 2012-07-24
- Lead Sponsor
- Genta Incorporated
- Target Recruit Count
- 580
- Registration Number
- NCT01573468
- Locations
- 🇩🇪
Krankenhaus Nordwest, Frankfurt, Germany
🇺🇸The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
🇨🇳National Cheng Kung University Hospital, Tainan, Taiwan
Study of Tesetaxel in Japanese Patients With Solid Tumors
- First Posted Date
- 2011-04-18
- Last Posted Date
- 2012-03-13
- Lead Sponsor
- Genta Incorporated
- Target Recruit Count
- 12
- Registration Number
- NCT01337310
- Locations
- 🇯🇵
Kinki University School of Medicine, Osaka-fu, Japan
Tesetaxel in Chemotherapy-naive Patients With Progressive, Castration-resistant Prostate Cancer
- First Posted Date
- 2011-02-15
- Last Posted Date
- 2012-07-24
- Lead Sponsor
- Genta Incorporated
- Target Recruit Count
- 57
- Registration Number
- NCT01296243
- Locations
- 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
🇺🇸The Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
🇺🇸University of Michigan Health System, Ann Arbor, Michigan, United States
Tesetaxel for Previously Treated Patients With Bladder Cancer
- Conditions
- First Posted Date
- 2010-10-07
- Last Posted Date
- 2012-07-11
- Lead Sponsor
- Genta Incorporated
- Target Recruit Count
- 33
- Registration Number
- NCT01215877
- Locations
- 🇮🇹
San Camillo Forlanini Hospital, Rome, Italy
🇺🇸Memorial Sloan-Kettering Cancer Center, New York, New York, United States
🇺🇸Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, United States
Tesetaxel as Second-line Therapy for Patients With Advanced Gastric Cancer
- First Posted Date
- 2010-03-29
- Last Posted Date
- 2012-03-15
- Lead Sponsor
- Genta Incorporated
- Target Recruit Count
- 27
- Registration Number
- NCT01095120
- Locations
- 🇰🇷
Severance Hospital, Yonsei University Health System, Seoul, Korea, Republic of
🇺🇸Northwestern Medical Faculty Foundation, Chicago, Illinois, United States
🇺🇸Abramson Cancer of the University of Pennsylvania at Perelman Center for Advanced Medicine, Philadelphia, Pennsylvania, United States
Tesetaxel as Second-line Therapy for Patients With Advanced Melanoma and Normal Serum LDH
- Conditions
- First Posted Date
- 2010-03-25
- Last Posted Date
- 2011-11-08
- Lead Sponsor
- Genta Incorporated
- Target Recruit Count
- 27
- Registration Number
- NCT01092585
- Locations
- 🇺🇸
The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.